Provided By PR Newswire
Last update: Sep 16, 2024
LONDON, Sept. 16, 2024 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced that it has entered into an extension of its already existing exclusive distribution agreement with Cosmos Health Inc. (Nasdaq: COSM) ("Cosmos") to commercialize Mpox Virus Real-Time PCR Detection Kits in countries in the Gulf Cooperation Council ("GCC"). It had previously signed an agreement for exclusive distribution in Greece & Cyrprus and non-exclusive distribution throughout Europe.
Read more at prnewswire.com0.9533
+0.02 (+2.3%)
0.6283
-0.02 (-2.44%)
Find more stocks in the Stock Screener